Liftstream is an executive search recruitment company in the life sciences sector
Novimmune sees immunotherapy and orphan focus attract new capital
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged acute lymphocytic leukemia, Alexion, Angel investment, Ariad, bioValley, Covagen, Crohn's disease, Dr Jonathan hepple, Geneva, Hemophagocytic lymphohistiocytosis, Lomard odier ventures, Merck Serono, monoclonoal antibody therapeutics, NovImmune, Nyon, Rare Disease, renal allograft transplantation, Rosetta Capital, Shire, Switzerland, Vertex Pharmaceuticals, Zug
Leave a comment
Shire expands rare disease reach with Viropharma Purchase
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged acquisition, Basingstoke, Cinryze, clinical development, EU, Flemming Ornskov, Geneva, immune disorder hereditary angioedema, Lotus Tissue Repair, marketed products, Pipeline, regulatory approval, restructure, SARcode, Shire, Shire HGT, Shire Rare Disease, Switzerland, USA, Viropharma, Zug
Leave a comment
Day 1 The World Orphan Drug Congress – Geneva
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Adaptive Licensing, clinical development, Clinical Trial Design, Corporate Development and Partnerships, EURORDIS, Geneva, HTA, IRDiRC, Market Access, Nyon, Orphan drugs, pricing and reimbursement, rare diseases, Shire HGT, Theresa Heggie, world orphan drug congress, world orphan drug congress 2012, Yann Le Cam
Leave a comment
Merck Serono staff navigate new horizons
The proposal and counter proposals have been submitted and reviewed. The employee protests roll on, although partly muted by legal disputes and management negotiations. Now though, it is decided. The shutters will come down at Merck Serono in Geneva. An estimated workforce of 1250 people will be affected, their lives driven in new directions.